Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 1 3Phase 2 2Phase NA 1Phase 3 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1

Conditions

Stomach Neoplasms 1Recurrence 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 109Paclitaxel 65Cyclophosphamide 65Cisplatin 60Carboplatin 56Gemcitabine 48Radiotherapy 45Nivolumab 44fludarabine 38Docetaxel 38Pemetrexed 33Dexamethasone 32Capecitabine 32Lenalidomide 26fludarabine phosphate 25Rituximab 25Radiation 25Ipilimumab 25Doxorubicin 25Irinotecan 24Bevacizumab 24Azacitidine 24Vorinostat 23Vincristine 22Cytarabine 22Temozolomide 20Etoposide 20Oxaliplatin 19Fluorouracil 19atezolizumab 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Has results × PEGPH20 × Clear all
NCT02563548 2020-02-07

A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors

Halozyme Therapeutics

Phase 1 Completed
56 enrolled 24 charts
Gastrointestinal

Stomach Neoplasms

NCT03267940 2020-02-07

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Halozyme Therapeutics

Phase 1 Terminated
85 enrolled 17 charts
Gastrointestinal

Cholangiocarcinoma

NCT02346370 2019-02-08

PRIMAL

Halozyme Therapeutics

Phase 1 Terminated
16 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡